Literature DB >> 23904766

Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer.

F Morgillo1, F De Vita, G Antoniol, M Orditura, P P Auriemma, M R Diadema, E Lieto, B Savastano, L Festino, M M Laterza, A Fabozzi, J Ventriglia, A Petrillo, F Ciardiello, A Barbarisi, F Iovino.   

Abstract

Increased insulin-like growth factor (igf) signalling has been observed in breast cancer, including endocrine-responsive cancers, and has been linked to disease progression and recurrence. In particular, igf-1 has the ability to induce and promote lymphangiogenesis through the induction of vascular endothelial growth factor C (vegfc). In the present study, we analyzed serum and tumour samples from 60 patients with endocrine-positive breast cancer to determine the expression and the possible relationship of circulating igf-1, igf binding protein 3 (igfbp3), and vegfc with the presence of lymphatic metastasis and other immunohistochemical parameters. The analysis revealed a clear and significant correlation between high basal levels of igf-1, igfbp3, and vegfc and lymph node metastasis in endocrine-responsive breast cancer. In addition, expression of those molecules was significantly higher in breast cancer patients than in healthy control subjects. Those findings may enable more accurate prediction of prognosis in patients with breast cancer.

Entities:  

Keywords:  Breast cancer; igf-1; vegfc

Year:  2013        PMID: 23904766      PMCID: PMC3728056          DOI: 10.3747/co.20.1380

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  24 in total

Review 1.  Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Authors:  Deepali Sachdev; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 2.  Role of the insulin-like growth factor family in cancer development and progression.

Authors:  H Yu; T Rohan
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

Review 3.  Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.

Authors:  E Surmacz; M Bartucci
Journal:  J Exp Clin Cancer Res       Date:  2004-09

Review 4.  The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models.

Authors:  Shoshana Yakar; Derek Leroith; Pnina Brodt
Journal:  Cytokine Growth Factor Rev       Date:  2005 Aug-Oct       Impact factor: 7.638

5.  The insulin-like growth factors and breast cancer--revisited.

Authors:  D Yee
Journal:  Breast Cancer Res Treat       Date:  1998-02       Impact factor: 4.872

6.  Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.

Authors:  B Enholm; T Karpanen; M Jeltsch; H Kubo; F Stenback; R Prevo; D G Jackson; S Yla-Herttuala; K Alitalo
Journal:  Circ Res       Date:  2001-03-30       Impact factor: 17.367

7.  Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo.

Authors:  Krisztina Kovács de Ostrovich; Isabel Lambertz; Jennifer K L Colby; Jie Tian; Joyce E Rundhaug; Dennis Johnston; Claudio J Conti; John DiGiovanni; Robin Fuchs-Young
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

8.  Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases.

Authors:  Yan Gu; Xiaoliang Qi; Shanyu Guo
Journal:  Clin Exp Metastasis       Date:  2008-05-30       Impact factor: 5.150

9.  Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.

Authors:  F Iovino; F Ferraraccio; M Orditura; G Antoniol; F Morgillo; T Cascone; M R Diadema; G Aurilio; G Santabarbara; R Ruggiero; C Belli; E Irlandese; M Fasano; F Ciardiello; E Procaccini; F Lo Schiavo; G Catalano; F De Vita
Journal:  Cancer Invest       Date:  2008 Apr-May       Impact factor: 2.176

10.  Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer.

Authors:  Axel Muendlein; Alois H Lang; Simone Geller-Rhomberg; Thomas Winder; Klaus Gasser; Heinz Drexel; Thomas Decker; Elisabeth Mueller-Holzner; Martina Chamson; Christian Marth; Michael Hubalek
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-23       Impact factor: 4.553

View more
  9 in total

1.  Metformin may protect nondiabetic breast cancer women from metastasis.

Authors:  Sahar Mohammed El-Haggar; Nagla A El-Shitany; Mohamed Farouk Mostafa; Noha Ahmed El-Bassiouny
Journal:  Clin Exp Metastasis       Date:  2016-02-22       Impact factor: 5.150

2.  Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer.

Authors:  Diego Pérez; Alexander Rohde; Gonzalo Callejón; Elisabeth Pérez-Ruiz; Isabel Rodrigo; Francisco Rivas-Ruiz; Belen Ramos; Francisco Medina; Rosa Villatoro; Maximino Redondo; Irene Zarcos; Claudio Maañón; Antonio Rueda
Journal:  Tumour Biol       Date:  2015-06-24

3.  Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma.

Authors:  Ashuvinee Elangovan; Jagmohan Hooda; Laura Savariau; Susrutha Puthanmadhomnarayanan; Megan E Yates; Jian Chen; Daniel D Brown; Priscilla F McAuliffe; Steffi Oesterreich; Jennifer M Atkinson; Adrian V Lee
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

Review 4.  The role of the insulin-like growth factor-1 system in breast cancer.

Authors:  Panagiotis F Christopoulos; Pavlos Msaouel; Michael Koutsilieris
Journal:  Mol Cancer       Date:  2015-02-15       Impact factor: 27.401

Review 5.  Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?

Authors:  Hanna A Zielinska; Amit Bahl; Jeff Mp Holly; Claire M Perks
Journal:  Breast Cancer (Dove Med Press)       Date:  2015-01-19

6.  Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.

Authors:  A H Thomson; J McGrane; J Mathew; J Palmer; D A Hilton; G Purvis; R Jenkins
Journal:  Br J Cancer       Date:  2016-02-23       Impact factor: 7.640

7.  A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

Authors:  John Crown; Javier Cortés; Peter Schmid; Marie-Paule Sablin; Jonas Bergh; Seock-Ah Im; Yen-Shen Lu; Noelia Martínez; Patrick Neven; Keun Seok Lee; Serafín Morales; J Alejandro Pérez-Fidalgo; Douglas Adamson; Anthony Gonçalves; Aleix Prat; Guy Jerusalem; Laura Schlieker; Rosa-Maria Espadero; Thomas Bogenrieder; Dennis Chin-Lun Huang
Journal:  Breast Cancer Res       Date:  2021-01-15       Impact factor: 6.466

8.  Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations.

Authors:  Pinchas Cohen; Wayne Weng; Alan D Rogol; Ron G Rosenfeld; Anne-Marie Kappelgaard; John Germak
Journal:  Clin Endocrinol (Oxf)       Date:  2014-02-07       Impact factor: 3.478

9.  Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk.

Authors:  Weifeng Tang; Shuchen Chen; Jun Liu; Chao Liu; Yafeng Wang; Mingqiang Kang
Journal:  J Cell Biochem       Date:  2018-10-18       Impact factor: 4.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.